Effects of Simvastatin on Uterine Leiomyoma Size

Launched by JOHNS HOPKINS UNIVERSITY · Jan 9, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a medication called simvastatin on the size of uterine fibroids, which are non-cancerous tumors that can cause symptoms like heavy menstrual bleeding and pelvic pain. The study is currently recruiting female participants aged between 18 and 55 who have been diagnosed with uterine fibroids that are larger than 3 cm. To be eligible, participants should also have experienced heavy menstrual bleeding at least three times in the past six months and have a body mass index (BMI) of less than 45.

If you decide to participate, you will receive the medication and be monitored for changes in the size of your fibroids. The trial aims to see if simvastatin can help reduce fibroid size and alleviate symptoms. It's important to note that certain medical conditions and treatments can exclude you from participating, so a thorough screening will be conducted. This study is an opportunity to contribute to research that could improve treatment options for women with uterine fibroids.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Signed informed written consent.
• • Gender: female.
• • Age: 18-55 years at time of signing consent.
• • BMI of subjects: \< 45 kg/m2.
• * Uterine fibroids:
• • Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).
• • Number: any number of fibroids.
• • Location: submucosal or intramural.
• • At least one fibroid of diameter \> 3cm.
• * Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB), defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy bleeding may include, but are not limited to the following:
• • Requires the use of double protection to manage menstrual bleeding.
• • Menstrual bleeding accompanied by the sensation of "gushing" or "flooding".
• • Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.
• • Regularly needs to change the tampon or sanitary pad at night or regularly soils bedclothes.
• • Heavy bleeding that affects work, school, or social activities.
• • Pelvic pain/ pressure likely caused by fibroids.
• • Plan for surgery (hysterectomy or myomectomy).
• • Normal Pap smear within the last year.
• • Use of contraception during study such as non-hormonal oral contraceptives, intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives, abstinence or sterilization.
• Exclusion Criteria:
• • Pregnancy or lactation.
• • Previous or current uterine, cervical or ovarian cancer.
• • Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months).
• • Suspicion of leiomyosarcoma.
• • Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).
• • Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass).
• • Menopausal status.
• • Surgery is urgently indicated (\< 3 months) for medical or social reasons.
• • Hemoglobin ≤ 6 g/dL.
• • Currently enrolled in another investigational study.
• • Mental condition or other barrier preventing informed written consent.
• • Allergy or hypersensitivity to simvastatin.
• • Current use of simvastatin or other drugs of the same class.
• • Concomitant administration of strong CYP3A4 inhibitors including itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing products.
• • Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil, diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and grapefruit juice.
• • Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase \> 2 s.d. above the normal range at screening visit)
• • Known increased risk or diagnosis of a myopathy.